Temsirolimus Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 25 mg/ml, 100 mg
Reference Brands: Torisel (USA)
Category:
Oncology Cancer Care
Temsirolimus is available in Injection
and strengths such as 25 mg/ml, 100 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Temsirolimus is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Temsirolimus can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Temsirolimus is an intravenous anticancer medication sold under the brand name Torisel and is primarily used for the treatment of advanced renal cell carcinoma (RCC). It is a derivative and prodrug of sirolimus and works by inhibiting the mammalian target of rapamycin (mTOR), a key protein kinase that regulates cell growth, proliferation, metabolism, and angiogenesis. By blocking mTOR signaling, temsirolimus slows the growth and division of cancer cells and helps reduce tumor progression.
Developed by Wyeth Pharmaceuticals, temsirolimus was approved by the U.S. Food and Drug Administration (FDA) in May 2007 and by the European Medicines Agency (EMA) in November 2007. It is administered intravenously under medical supervision, typically in patients with advanced or poor-risk RCC. Temsirolimus provides a targeted therapeutic option for patients who may not be suitable for surgical interventions, offering a mechanism-based approach to controlling tumor growth.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing